You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Claims for Patent: 11,786,531

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 11,786,531

Title:	Methods of treating B-cell proliferative disorder
Abstract:	Provided herein is a method of treating a patient having a B-cell proliferative disorder, the method comprising administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, wherein the patient is characterized by being administered with a moderate CYP3A inducer. In one embodiment, zanubrutinib is administered at a dose of about 320 mg twice a day, or at a total daily dose of about 640 mg.
Inventor(s):	Jason Paik, Tommi Salmi, Ying Ou
Assignee:	BeiGene Switzerland GmbH
Application Number:	US18/098,938
Patent Claims:	1. A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg, and the moderate CYP3A inducer, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). 2. The method of claim 1, wherein zanubrutinib is administered at a dose of about 320 mg twice a day. 3. The method of claim 1, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL). 4. The method of claim 1, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL). 5. The method of claim 1, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM). 6. The method of claim 1, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL). 7. The method of claim 1, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL). 8. The method of claim 1, wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin. 9. The method of claim 1, wherein the administration prolongs the progression-free survival (PFS) time of the patient as compared to the PFS time of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily. 10. The method of claim 1, wherein the administration causes lower rate of atrial fibrillation or flutter as compared to the rate of atrial fibrillation or flutter of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily. 11. A method of treating or delaying progression of a B-cell proliferative disorder in a patient, the method comprising determining whether the patient is being treated with a moderate CYP3A inducer; and if the patient is being treated with a moderate CYP3A inducer, concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg; and the moderate CYP3A inducer, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). 12. The method of claim 11, wherein zanubrutinib is administered at a dose of about 320 mg twice a day. 13. The method of claim 11, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL). 14. The method of claim 11, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL). 15. The method of claim 11, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM). 16. The method of claim 11, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL). 17. The method of claim 11, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL). 18. The method of claim 11, wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin. 19. The method of claim 11, wherein the administration prolongs the progression-free survival (PFS) time of the patient as compared to the PFS time of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily. 20. The method of claim 11, wherein the administration causes lower rate of atrial fibrillation or flutter as compared to the rate of atrial fibrillation or flutter of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily. 21. A method of treating or delaying progression of a B-cell proliferative disorder in a patient receiving a moderate CYP3A inducer, the method comprising assessing the patient as to whether administration of the moderate CYP3A inducer can be avoided; and if the administration of the moderate CYP3A inducer cannot be avoided, concomitantly administering to the patient zanubrutinib, or a pharmaceutically acceptable salt thereof, at a total daily dose of about 640 mg, and the moderate CYP3A inducer, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or follicular lymphoma (FL). 22. The method of claim 21, wherein zanubrutinib is administered at a dose of about 320 mg twice a day. 23. The method of claim 21, wherein the B-cell proliferative disorder is chronic lymphocytic leukemia (CLL). 24. The method of claim 21, wherein the B-cell proliferative disorder is small lymphocytic lymphoma (SLL). 25. The method of claim 21, wherein the B-cell proliferative disorder is Waldenström macroglobulinemia (WM). 26. The method of claim 21, wherein the B-cell proliferative disorder is mantle cell lymphoma (MCL). 27. The method of claim 21, wherein the B-cell proliferative disorder is marginal zone lymphoma (MZL). 28. The method of claim 21, wherein the moderate CYP3A inducer is rifabutin, bosentan, efavirenz, etravirine, modafinil, phenobarbital or nafcillin. 29. The method of claim 21, wherein the administration prolongs the progression-free survival (PFS) time of the patient as compared to the PFS time of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily. 30. The method of claim 21, wherein the administration causes lower rate of atrial fibrillation or flutter as compared to the rate of atrial fibrillation or flutter of a comparable patient orally administered with ibrutinib at a dose of 420 mg once daily.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.